XFOR vs MTRX Comparison

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.